info:eu-repo/semantics/article
Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits
Fecha
2009-02Registro en:
D'Anunzio, Verónica; Donato, Pablo Martín; Erni, Lukas; Miksztowicz, Verónica Julieta; Buchholz, Bruno; et al.; Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits; Lippincott Williams; Journal Of Cardiovascular Pharmacology; 53; 2; 2-2009; 137-144
0160-2446
CONICET Digital
CONICET
Autor
D'Anunzio, Verónica
Donato, Pablo Martín
Erni, Lukas
Miksztowicz, Verónica Julieta
Buchholz, Bruno
Lorenzo Carrión, María Cristina
Schreier, Laura Ester
Wigdorovitz de Wikinski, Regina Luisa
Gelpi, Ricardo Jorge
Berg, Gabriela Alicia
Basso, Nidia
Resumen
There is evidence that statin treatment before ischemia protects myocardium from ischemia/reperfusion injury. Objective: to determine whether rosuvastatin administered during reperfusion modifies infarct size and the recovery of postischemic ventricular dysfunction in normo and hypercholesterolemic rabbit. Additionally, we also evaluated the role of MMP-2 activation. Langendorff-perfused rabbit hearts were subjected to 30 minutes of ischemia and 120 minutes of reperfusion. In group 2, we added rosuvastatin after 30 minutes of ischemia and from the beginning of reperfusion. In group 3, an MMP inhibitor (doxycycline) was administered during the first 2 min of reperfusion. Finally, we repeated these groups but in hypercholesterolemic rabbits (Groups 4, 5 and 6). The infarct size was 16.6±2.6% in group 1 and 25.6±2.7% in group 4. Rosuvastatin reduced infarct size to 4.5±1.1% and 5.5±1.6% in groups 2 and 5, respectively (p<0.05). Rosuvastatin significantly decreased MMP-2 activity during reperfusion and doxycycline induced an inhibition of MMP-2 activity and a reduction of infarct size in normo (4.9±0.9 %) and hypercholesterolemic animals (8.3±1.6%) (p<0.05). Rosuvastatin reduces infarct size and attenuates MMP-2 activity. These data and the correlation between MMP-2 and infarct size suggests that MMP-2 plays an important role in the mechanisms of cardioprotection afforded by rosuvastatin.